首页> 美国卫生研究院文献>Current Controlled Trials in Cardiovascular Medicine >Phase II study of two dose schedules of C.E.R.A. (Continuous Erythropoietin Receptor Activator) in anemic patients with advanced non-small cell lung cancer (NSCLC) receiving chemotherapy

【2h】

Phase II study of two dose schedules of C.E.R.A. (Continuous Erythropoietin Receptor Activator) in anemic patients with advanced non-small cell lung cancer (NSCLC) receiving chemotherapy

机译：II.C.E.R.A.两种剂量方案的II期研究。持续性促红细胞生成素受体激活剂治疗晚期非小细胞肺癌（NSCLC）贫血患者接受化疗

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

摘要
著录项
相似文献
相关主题

摘要

BackgroundC.E.R.A. (Continuous Erythropoietin Receptor Activator) is an innovative agent with unique erythropoietin receptor activity and prolonged half-life. This study evaluated C.E.R.A. once weekly (QW) or once every 3 weeks (Q3W) in patients with anemia and advanced non-small cell lung cancer (NSCLC) receiving chemotherapy.

机译：背景C.E.R.A. （连续促红细胞生成素受体激活剂）是一种具有独特促红细胞生成素受体活性和延长的半衰期的创新药物。这项研究评估了C.E.R.A.接受化疗的贫血和晚期非小细胞肺癌（NSCLC）患者每周一次（QW）或每3周一次（Q3W）。

著录项

期刊名称 Current Controlled Trials in Cardiovascular Medicine
作者
Vera Hirsh; John Glaspy; Paul Mainwaring; Christian Manegold; Rodryg Ramlau; Joseph E Eid;
展开▼
作者单位

展开▼
年(卷),期 2007(8),-1
年度 2007
页码 8
总页数 15
原文格式 PDF
正文语种
中图分类心血管疾病;
关键词

相似文献

外文文献
中文文献
专利

1. Phase II study of two dose schedules of C.E.R.A. (Continuous Erythropoietin Receptor Activator) in anemic patients with advanced non-small cell lung cancer (NSCLC) receiving chemotherapy [J] . Vera Hirsh, John Glaspy, Paul Mainwaring, Trials . 2007,第1期

机译：两项C.E.R.A.剂量方案的II期研究。连续性促红细胞生成素受体激活剂治疗晚期非小细胞肺癌（NSCLC）贫血患者接受化疗
2. Effects of CERA (continuous erythropoietin receptor activator) in patients with advanced non-small-cell lung cancer (NSCLC) receiving chemotherapy: results of a phase II study. [J] . Gascon P, Pirker R, Del Mastro L, Annals of oncology: official journal of the European Society for Medical Oncology . 2010,第10期

机译：CERA（持续促红细胞生成素受体激活剂）对接受化疗的晚期非小细胞肺癌（NSCLC）患者的影响：II期研究的结果。
3. Effects of CERA (continuous erythropoietin receptor activator) in patients with advanced non-small-cell lung cancer (NSCLC) receiving chemotherapy: results of a phase II study. [J] . Gascon P, Pirker R, Del Mastro L, Annals of oncology: official journal of the European Society for Medical Oncology . 2010,第10期

机译：CERA（持续促红细胞生成素受体激活剂）对接受化疗的晚期非小细胞肺癌（NSCLC）患者的影响：II期研究的结果。
4. The clinical efficacy of transfusion of cytokine-induced killer cells combined with chemotherapy and XiaoJi decoction in patients with stage IIIB/IV non-small cell lung cancer [C] . Liuning Li, Jiaying Liu, Xiaoshu Chai, IEEE International Conference on Bioinformatics and Biomedicine . 2014

机译：细胞因子诱导的杀伤细胞输注结合化学疗法和消积汤治疗IIIB / IV期非小细胞肺癌的临床疗效
5. Assessing the effectiveness of palliative chemotherapy for non-small cell lung cancer: A phase IV study of patients treated at Ontario's cancer centres [D] . Harrison, Lyndsay Dawn. 2012

机译：评估姑息化疗对非小细胞肺癌的有效性：在安大略省癌症中心接受治疗的患者的IV期研究
6. Prospective Evaluation of First-Line Erlotinib in Advanced Non-Small Cell Lung Cancer (NSCLC) Carrying an Activating EGFR Mutation: A Multicenter Academic Phase II Study in Caucasian Patients (FIELT) [O] . Jacques De Grève, Jan Van Meerbeeck, Johan F. Vansteenkiste, -1

机译：一线厄洛替尼治疗晚期非小细胞肺癌（NSCLC）进行EGFR活化突变的前瞻性评估：白人患者多中心学术II期研究（FIELT）
7. Phase II study of two dose schedules of C.E.R.A. (Continuous Erythropoietin Receptor Activator) in anemic patients with advanced non-small cell lung cancer (NSCLC) receiving chemotherapy [O] . Vera Hirsh, John Glaspy, Paul Mainwaring, 2007

机译：II.C.E.R.A.两种剂量方案的II期研究。持续性促红细胞生成素受体激活剂治疗晚期非小细胞肺癌（NSCLC）贫血患者接受化疗

Phase II study of two dose schedules of C.E.R.A. (Continuous Erythropoietin Receptor Activator) in anemic patients with advanced non-small cell lung cancer (NSCLC) receiving chemotherapy

摘要

著录项

相似文献

相关主题

期刊订阅